UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
“The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.